Andrew J. Roth

October 03, 2016

The treatment of TNBC is rapidly evolving, with immotherapies, AR-targeted agents and targeted therapies.

September 22, 2016

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

July 15, 2016

A decade after the FDA approved the first vaccine to prevent human papillomavirus (HPV), a new report from the Centers for Disease Control and Prevention (CDC) shows that the incidence of HPV-associated cancers is rising, with the number of HPV-associated cancers diagnosed annually between 2008 and 2012 increasing by approximately 16% compared with the previous 5-year period.

July 07, 2016

The FDA has approved dronabinol oral solution (Syndros) to treat chemotherapy-induced nausea and vomiting (CINV) in patients who have not responded to conventional antiemetic therapies.

June 30, 2016

Results of a small study exploring the use of frozen gloves and socks in women receiving paclitaxel chemotherapy for their breast cancer suggest the approach may hold promise for the relief of chemotherapy-induced peripheral neuropathy (CIPN).

June 21, 2016

Coping with the aftermath of cancer and cancer treatment can be especially difficult for survivors of head and neck cancer, according to Ann Marie Flores, PT, PhD, CLT.

June 17, 2016

While it is known that overweight and obese survivors of breast cancer experience poorer outcomes, gaps remain with regard to risk perception and communication between survivors and health care providers.

June 15, 2016

Oncology nurses receive a steady stream of information on the benefits of exercise for health and wellness—not just a way to help prevent cancer and lower risk for the general population, but to improve quality of life and reduce the risk of recurrence for patients and survivors.

June 10, 2016

In a small pilot study, presented at the recent 2016 ASCO Annual Meeting, researchers are evaluating whether wearable activity monitors can help clinicians to better assess patient well-being between office visits.

May 27, 2016

Though there are few therapeutic options for patients with myelofibrosis, ruxolitinib (Jakafi) represents an important look towards the future, according to Maureen E. Thyne, a physician assistant in the Outpatient Leukemia Service at Weill Cornell Medical College.